梅花生物(600873) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was approximately RMB 6.94 billion, representing a year-on-year increase of 5.10%[4] - The net profit attributable to shareholders for Q3 2023 was approximately RMB 789.67 million, a decrease of 9.05% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was approximately RMB 691.98 million, down 19.02% year-on-year[4] - The basic earnings per share for Q3 2023 was RMB 0.27, reflecting a decrease of 3.57% compared to the previous year[4] - The weighted average return on equity for Q3 2023 was 5.54%, a decrease of 1.44 percentage points from the previous year[4] - The total comprehensive income for the third quarter was ¥2,447,973,619.90, compared to ¥3,416,988,074.17 in the previous year, a decrease of about 28.38%[17] - The company's long-term borrowings decreased to ¥2,708,924,876.77 from ¥3,676,011,413.26, a decline of approximately 26.36%[13] - Basic and diluted earnings per share for Q3 2023 were both ¥0.72, compared to ¥1.11 in Q3 2022, indicating a decline of approximately 35.1%[18] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately RMB 24.23 billion, a decrease of 1.05% from the end of the previous year[4] - The equity attributable to shareholders at the end of Q3 2023 was approximately RMB 14.18 billion, an increase of 4.92% compared to the end of the previous year[4] - Total assets decreased to ¥24,233,637,909.60 from ¥24,490,222,471.46, a decline of approximately 1.05%[13] - Total liabilities decreased to ¥10,053,151,691.39 from ¥10,974,089,118.69, a reduction of about 8.36%[13] - The company's fixed assets increased to RMB 11,629,762,535.68 from RMB 9,911,708,010.15, reflecting a growth of approximately 17.31%[12] - The total non-current assets increased to RMB 14,798,946,512.61 from RMB 14,577,638,970.15, showing a growth of approximately 1.52%[12] Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 10.47% compared to the previous year, attributed to reduced sales collections and increased raw material costs[6] - Cash inflow from operating activities for the first nine months of 2023 was ¥22,505,535,051.46, a decrease of about 2.1% from ¥22,997,408,878.67 in the same period of 2022[19] - Net cash flow from operating activities for the first nine months of 2023 was ¥4,884,286,182.54, down 10.5% from ¥5,455,580,471.51 in the previous year[19] - Cash inflow from investment activities for the first nine months of 2023 was ¥29,103,914.50, compared to a cash outflow of ¥34,435,357.45 in the same period of 2022[20] - Net cash flow from investment activities for the first nine months of 2023 was -¥1,453,883,158.21, an improvement from -¥2,531,821,725.50 in the previous year[20] - Cash inflow from financing activities for the first nine months of 2023 was ¥3,597,740,538.77, significantly higher than ¥1,980,634,410.15 in the same period of 2022[20] - Net cash flow from financing activities for the first nine months of 2023 was -¥2,386,027,386.63, an improvement from -¥3,038,275,411.91 in the previous year[20] - The ending balance of cash and cash equivalents as of September 30, 2023, was ¥5,203,814,144.66, up from ¥3,202,289,539.31 at the end of Q3 2022[20] Market and Strategic Developments - The company established a new wholly-owned subsidiary, Zhuhai Hengqin Meihua Biotechnology Co., Ltd., with an investment of RMB 50 million to expand its international market presence[9] - The company plans to set up additional subsidiaries in Hong Kong, Cayman Islands, and Singapore as part of its international expansion strategy[9] - The company has committed to strict compliance with regulations regarding share repurchase and timely information disclosure[9] Revenue and Costs - The company's revenue for the year-to-date period was approximately RMB 20.53 billion, a decrease of 1.42% year-on-year, mainly due to lower prices for key products[6] - Operating revenue for the first three quarters of 2023 was ¥20,526,171,453.75, a slight decline from ¥20,821,165,705.82, reflecting a decrease of about 1.42%[15] - Operating costs increased to ¥18,070,945,779.49 from ¥16,877,698,645.08, an increase of approximately 7.06%[15] - Research and development expenses rose to ¥234,168,723.06 from ¥198,828,242.72, marking an increase of about 17.69%[15] - The company's gross profit margin decreased from 21.79% in the previous year to 18.48% in Q3 2023, primarily due to lower prices for key products and higher corn prices[6]